Phytosterolemia in children with parenteral nutrition-associated cholestatic liver disease

P T Clayton1, A Bowron, K A Mills

  • 1Metabolic Disease Unit, Institute of Child Health, London, England.

Gastroenterology
|December 1, 1993
PubMed

Insights

High phytosterol levels in children receiving parenteral nutrition (PN) are linked to cholestatic liver disease and thrombocytopenia. Reducing lipid emulsion intake improved these conditions, suggesting phytosterolemia contributes to PN complications.

Area of Science:

  • Biochemistry
  • Pediatrics
  • Clinical Nutrition

Background:

  • Parenteral nutrition (PN) lipid emulsions contain phytosterols.
  • Phytosterols may accumulate and cause liver disease and thrombocytopenia in patients receiving PN.

Purpose of the Study:

  • To investigate the association between plasma phytosterol concentrations and PN-associated complications in children.
  • To determine if phytosterolemia contributes to cholestatic liver disease and thrombocytopenia in children receiving PN.

Main Methods:

  • Plasma sterol concentrations were measured using gas chromatography-mass spectrometry in 29 children receiving PN and 29 controls.
  • Children receiving PN were subgrouped based on the severity of liver disease (bilirubin and AST levels).

Main Results:

  • Children with severe PN-associated liver disease had significantly higher plasma phytosterol and sitostanol concentrations, comparable to hereditary phytosterolemia.
  • All 5 children with severe liver disease experienced intermittent thrombocytopenia.
  • Reducing lipid emulsion intake led to decreased plasma phytosterols and improved liver function and platelet counts in two patients.

Conclusions:

  • Children receiving PN with elevated plasma phytosterol concentrations exhibit cholestatic liver disease and thrombocytopenia.
  • Phytosterolemia is implicated as a potential contributor to the pathogenesis of PN-related complications.
Abstract

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...